PI3K抑制剂在淋巴瘤中的研究进展

Research Progress of Phosphatidylinositide 3-kinase Inhibitors in Lymphoma

磷脂酰肌醇-3-激酶(PI3K)/蛋白激酶B(PKB/Akt)/哺乳动物雷帕霉素靶蛋白(mTOR)信号通路的异常活化与包括恶性淋巴瘤在内的众多肿瘤的发生发展密切相关。目前,针对该通路的分子靶向治疗成为肿瘤领域的研究热点,部分PI3K抑制剂已进入淋巴瘤的临床试验中。PI3K抑制剂包括广谱PI3K抑制剂、选择性PI3K抑制剂及PI3K/mTOR双重抑制剂。由于淋巴瘤发病机制的复杂性,单靶点的PI3K抑制剂疗效往往有限,需联合化疗或其他靶向药物以提升抗肿瘤疗效。未来,应筛选出能预测PI3K抑制剂疗效的指标,使其成为淋巴瘤治疗的有效途径。

Abnormal activation of phosphatidylinositide3-kinase (PI3K)/protein kinase B(PKB/Akt)/mammalian target of rapamycin signaling pathway(mTOR) signaling pathway is closely related to the occurrence and development of many tumors,including malignant lymphoma.At present,molecular targeted therapy for this pathway has become a hot topic in the tumor field, and some PI3K inhibitors have entered the clinical trials of lymphoma.PI3K inhibitors include broad-spectrum PI3K inhibitors, selective PI3K inhibitors and PI3K/mTOR dual inhibitors.Because of the complexity of the pathogenesis of lymphoma,the efficacy of PI3K inhibitors with single target is often limited.It is necessary to combine chemotherapy or other targeted drugs to enhance the anti-tumor efficacy.In the future, indicators that can predict the efficacy of PI3K inhibitors should be screened,making it an effective way to treat lymphoma.